Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20996942 | 0.87 | PROKR1 (0.47) | PROKR1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL20996955 | 0.87 | PROKR1 (0.45) | TRPV1FNTAFNTBPROKR1CYP3A4 | |
| SCHEMBL20997176 | 0.85 | PROKR1 (0.42) | TRPV1FNTAFNTBPROKR1MAPT | |
| SCHEMBL20971774 | 0.84 | IDO1 (0.42) | PROKR1MAPTKDM4ENPSR1MAPK1 | |
| SCHEMBL20971759 | 0.84 | PROKR1 (0.43) | PROKR1MAPTFAAHKDM4ENPSR1 | |
| SCHEMBL20971843 | 0.82 | PROKR1 (0.40) | TRPV1FNTAFNTBPROKR1MAPT | |
| SCHEMBL20997175 | 0.82 | PROKR1 (0.41) | TRPV1PROKR1MAPTFAAHKDM4E | |
| SCHEMBL21061311 | 0.80 | PROKR1 (0.51) | TRPV1PROKR1MAPTMEN1KMT2A | |
| SCHEMBL15537076 | 0.79 | SRD5A2 (0.51) | PROKR1MAPTKMT2A | |
| SCHEMBL20996938 | 0.79 | PROKR1 (0.47) | TRPV1PROKR1CYP3A4CYP3A5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | NDUFAB1, FH, MT-ND1 | TRPV1 3515/4885FNTA 3449/4885FNTB 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.